CUPERTINO, Calif., Mar 18, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today the results from a pilot Phase III clinical study for its lead product in development, the CHRONOGESIC(TM) (sufentanil) Pain Therapy System for the treatment of chronic pain. The CHRONOGESIC product is undergoing clinical investigation for the treatment of stable, opioid […]
CUPERTINO, Calif., Jan. 30 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2001. The Company’s net loss attributable to common stockholders for the three months ended December 31, 2001 was $10.1 million or 21 cents per share, compared to $4.9 million or 11 cents
DURECT Corporation Reports Fourth Quarter 2001 and Year End Financial Results Read More »
CUPERTINO, Calif., Jan. 23 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it is sponsoring a symposium on novel drug delivery technologies at the 45th Annual Meeting of the Western Pharmacology Society (WPS) being held at the Hotel El Cid in Mazatlan, Sinaloa, Mexico, January 27th through February 1st, 2002. Dr. Randolph M. Johnson,
CUPERTINO, Calif., Jan 14, 2002 (BUSINESS WIRE) — In conjunction with DURECT Corporation’s (NASDAQ:DRRX) fourth quarter and year end 2001 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, January 30, 2002 at 4:30 p.m. EDT with Jim Brown, President and
CUPERTINO, Calif., Jan 4, 2002 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan H&Q 20th Annual Healthcare Conference. The conference is taking place January 7-10th at The Westin St. Francis Hotel in San Francisco. James E. Brown, DVM, Chief Executive Officer will be presenting at the
DURECT Corporation Presenting at the JPMorgan H&Q 20th Annual Healthcare Conference Read More »
CUPERTINO, Calif., Nov 16, 2001 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that ALZA Corporation has exercised its option to allow ALZA and Janssen Pharmaceutica Products, L.P., the right to begin negotiations for exclusive sales and marketing rights to DURECT’s lead pain management product, Chronogesic(TM) for the U.S. and Canada. Chronogesic(TM) is
CUPERTINO, Calif., Nov. 1 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced during its third quarter financial results conference call yesterday that the company has commenced its Phase III program for Chronogesic(TM), for the treatment of chronic pain. The primary objectives of the Phase III program are to continue to demonstrate that the product is safe,
DURECT Corporation Reports Initiation of Phase III Program for Chronogesic(TM Read More »
CUPERTINO, Calif., Nov. 1 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Twelfth Annual Health Care Conference. The conference is taking place November 5-7 at The Plaza in New York City. Thomas A. Schreck, Chief Financial Officer will be presenting at the conference on Monday, November
CUPERTINO, Calif., Oct. 31 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2001. The company’s net loss attributable to common stockholders for the three months ended September 30, 2001 was $8.9 million or 19 cents per share compared to $6.0 million, or 62 cents per share,
DURECT Corporation Reports Third Quarter 2001 Financial Results Read More »
CUPERTINO, Calif., Oct 25, 2001 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced yesterday research results showing in animal models that new blood vessels are formed and that blood flow to an ischemic heart can be restored following targeted delivery of fibroblast growth factor to the heart. Dr. Randolph M. Johnson, DURECT’s Vice President
